Moreau P, Attal M, Hulin C, et al. Phase 3 randomized study of daratumumab + bortezomib/thalidomide/dexamethasone (D-VTD) versus VTD in transplant-eligle newly diagnosed multiple myeloma: part 1 CASSIOPEIA results. 24th Congress of EHA, abstract S145.
ONCOTHROMB: nieuwe risicoscore voor kankergeassocieerde VTE
mei 2023 | Benigne hematologie, Longoncologie, Maag-darm-leveroncologie